Howard M. Sandler, MD
Guidelines in development from the American Society for Radiation Oncology (ASTRO), American Society of Clinical Oncology (ASCO), and the American Urological Association (AUA) will soon support for the use of hypofractionation in patients with prostate cancer, explains Howard M. Sandler, MD.
State of the Science Summit™ on Genitourinary Cancers, Sandler, chair, Department of Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, director, Samuel Oschin Comprehensive Cancer Institute, and professor of radiation oncology, Cedars-Sinai Medical Center, discussed the emergence of hypofractionation as a viable treatment approach for patients with prostate cancer.
OncLive: What developments have there been in the area of radiation oncology in prostate cancer?
One of the major trends in prostate cancer is a move toward hypofractionation. In treatment, we’ll use fewer radiation fractions than we used in the past. We would use up to 45 treatments over 9 weeks. That is a long time for individuals to come in every day for radiation therapy treatment. We are excited about the studies published in 2016 and 2017 that showed equivalent outcomes between dramatically shorter regimens and standard fractionation. The 2 regimens that were studied were 20 and 28 fraction regimens. Both studies were compared head to head with standard fractionation and were noninferior to one another.
... to read the full story